Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 32
  1. Apr 17, 2026 · 19:00 · ONCO · Neutral

    Onco-Innovations Management Overhaul Amidst Severe Valuation Erosion and Dilution Concerns

    Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development

    01
  2. Apr 17, 2026 · 18:14 · SHRX · Routine +

    Sharp Therapeutics Secures Tranche Financing Amidst Pipeline Pivot and Contingent Equity Hurdles

    Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting

    02
  3. Apr 17, 2026 · 16:30 · MRVL · Routine +

    Marvel Biosciences Closes Financing to Fuel Phase I Transition Amidst Patent Wins

    Marvel Biosciences Announces Closing of Convertible Debenture Offering

    03
  4. Apr 17, 2026 · 13:50 · EYE · Routine +

    FDA Approval Fails to Halt Post-IPO Decline as Liquidity Concerns Mount

    Canadian Securities Exchange Reports March 2026 Performance Figures

    04
  5. Apr 17, 2026 · 13:50 · APPT · Neutral

    UberDoc Health Technologies Corp.

    Canadian Securities Exchange Reports March 2026 Performance Figures

    05
  6. Apr 17, 2026 · 07:19 · VVTM · Material −

    Compliance Failure Overshadows Commercial Progress as Audit Deadline Missed

    VVT Med Announces Application for Management Cease Trade Order

    06
  7. Apr 16, 2026 · 18:04 · WOLF · Routine +

    Strategic Pivot to Human Health Validates Growth Model Despite Leverage

    GREY WOLF ANIMAL HEALTH REPORTS FOURTH QUARTER AND YEAR END 2025 FINANCIAL RESULTS

    07
  8. Apr 16, 2026 · 16:57 · KNE · Routine +

    Clinical Validation Continues as Commercial Restart Struggles to Generate Revenue

    Kane presents revyve data at wound care conference

    08
  9. Apr 16, 2026 · 16:30 · CRRX · Routine +

    Regulatory Stability Confirmed as CareRx Enters Profitability Phase

    CareRx Welcomes Stability in Long-Term Care Pharmacy Funding in Ontario

    09
  10. Apr 16, 2026 · 11:00 · VPT · Routine +

    TSXV Venture Exchange Listed Cardiac Imaging Platform

    The Infrastructure Play Hiding in Plain Sight Across Cardiac Care

    10
  11. Apr 16, 2026 · 09:15 · NRX · Neutral

    NurExone Extends Runway Amid Rising Burn Rate as IND Prep Continues

    NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    11
  12. Apr 16, 2026 · 09:00 · VPT · Routine +

    VentriPoint Expands Global Footprint Amidst Persistent Dilution Concerns

    The Quiet Shift Replacing Million-Dollar Heart Scanners With Software

    12
  13. Apr 16, 2026 · 08:01 · PHRM · Routine +

    PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

    PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

    13
  14. Apr 16, 2026 · 07:30 · BPC · Routine +

    Regulatory Clarity Focus

    The Precision Peptide Company Applauds FDA Action Advancing Regulatory Clarity for Peptide Therapies

    14
← Newer Older →